Alphatec (ATEC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
24 Feb, 2026Executive summary
Achieved Q4 2025 revenue of $213 million, up 20% year-over-year, and full-year revenue of $764 million, a 25% increase, driven by increased surgical volume and surgeon adoption.
Adjusted EBITDA for Q4 was $33 million (up 61% year-over-year, 16% margin), and $93 million for the full year (12% margin), marking significant profit margin expansion.
Free cash flow turned positive for the first full year, with $8 million in Q4 and $3 million for 2025, an improvement of $131 million year-over-year.
Net new surgeon users grew 23% in Q4 and 20% for the year, supporting durable growth and continued leadership in lateral and deformity spine procedures.
Maintained leadership in spine-focused procedural innovation, launching new platforms and expanding the procedural ecosystem.
Financial highlights
Q4 revenue: $213 million (+20% year-over-year); surgical revenue $190 million (+21%), EOS revenue $23 million (+14%).
Full-year revenue: $764 million (+25% year-over-year); surgical revenue $687 million (+26%), EOS revenue $77 million (+15%).
Q4 non-GAAP gross margin: 71%; full-year non-GAAP gross margin: 70%.
Q4 Adjusted EBITDA: $33 million (16% margin); full-year Adjusted EBITDA: $93 million (12% margin).
Ended Q4 with $161 million in cash and $60 million undrawn credit, totaling $221 million in available liquidity.
Outlook and guidance
2026 revenue guidance: $890 million (+17% year-over-year), with $805 million surgical and $85 million EOS revenue.
2026 Adjusted EBITDA guidance raised to $134 million (15% margin), up from $130 million.
Expected 2026 free cash flow of at least $20 million, with continued investment in inventory and PP&E.
Gross margin expected to approach 71% by end of 2026; operating expenses to grow ~11% vs. 17% revenue growth, driving ~400 bps operating margin improvement.
Revenue growth algorithm driven by continued surgeon adoption and utilization, with existing surgeons supporting a significant portion of 2026 volume.
Latest events from Alphatec
- Surgeon adoption, enabling tech, and disciplined capital deployment drive robust growth and share gains.ATEC
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Q3 2024 revenue up 27%, adjusted EBITDA positive, and liquidity boosted by $50M term loan.ATEC
Q3 202413 Feb 2026 - Q2 revenue up 25% to $146M, margin expansion, positive EBITDA, and guidance raised.ATEC
Q2 202413 Feb 2026 - Rapid growth driven by procedural innovation, margin leverage, and targeted expansion.ATEC
Jefferies Global Healthcare Conference1 Feb 2026 - Spine-focused innovation and informatics drive strong growth, profitability, and global expansion.ATEC
44th Annual J.P. Morgan Healthcare Conference30 Jan 2026 - Inventory investment to decline, supporting free cash flow break even in 2025 and robust growth.ATEC
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Competitive hires and tech innovation drive growth; EOS and margin expansion support future gains.ATEC
Stifel 2024 Healthcare Conference13 Jan 2026 - Aggressive growth, tech innovation, and strong sales force drive long-term market expansion.ATEC
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Rapid, profitable growth and market share gains driven by innovation, informatics, and robotics.ATEC
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026